HANSA BIOPHARMA

# Investor Presentation

H.C Wainwright Annual Global Investment Conference
New York City September 12, 2022

Klaus Sindahl
*Head of Investor Relations*

# Forward-looking statements

This presentation may contain certain forward-looking statements and forecasts based on our current expectations and beliefs regarding future events and are subject to significant uncertainties and risks since they relate to events and depend on circumstances that will occur in the future. Some of these forward-looking statements, by their nature, could have an impact on Hansa Biopharma's business, financial condition and results of operations [or that of its parent, affiliate, or subsidiary companies]. Terms such as "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those projected, whether expressly or impliedly, in a forward-looking statement or affect the extent to which a particular projection is realized. Such factors may include, but are not limited to, changes in implementation of Hansa Biopharma's strategy and its ability to further grow; risks and uncertainties associated with the development and/or approval of Hansa Biopharma's product candidates; ongoing clinical trials and expected trial results; the ability to commercialize imlifidase if approved; changes in legal or regulatory frameworks, requirements, or standards; technology changes and new products in Hansa Biopharma's potential market and industry; the ability to develop new products and enhance existing products; the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors.

The factors set forth above are not exhaustive and additional factors could adversely affect our business and financial performance. We operate in a very competitive and rapidly changing environment, and it is not possible to predict all factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

Hansa Biopharma expressly disclaims any obligation to update or revise any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or otherwise, and disclaims any express or implied representations or warranties that may arise from any forward-looking statements. You should not rely upon these forward-looking statements after the date of this presentation.



HANSA BIOPHARMA

# Hansa Biopharma today

Successful track record...
Strong momentum...
Promising future...

## A validated technology

**VALIDATION ACROSS THREE AREAS**

- Approval in kidney transplantations
- Proof of concept in autoimmune diseases
- Partnerships to explore gene therapy

## Idefirix® is our first approved drug in Europe*

**EUROPE KIDNEY TRANSPLANTS**

For highly sensitized patients in Europe

## Broad pipeline in transplantation and autoimmunity

**PROGRAMS IN CLINICAL DEVELOPMENT**

US kidney transplants
Anti-GBM
Guillain-Barré syndrome (GBS)
Antibody mediated kidney transplant rejection (AMR)

## Established a high-performance organization

**NEW COMPETENCIES ADDED**

145 employees June 2022 (~3x in 3 years)

Highly qualified team with 20 years on average in life science

Purpose driven culture

## With current cash position Hansa is financed through 2024

**FINANCIALS**

SEK 617 in Cash and short term investments (USD ~60m) June 2022

SEK ~1.3bn (USD ~130m) post NovaQuest financing transaction carried out July 2022

## Created shareholder value and diversified our ownership base

**MARKET CAPITALISATION (USD): ~300m**

Listed on Nasdaq Stockholm

18,000 shareholders

Foreign ownership make up ~40% through leading international life science specialist funds


*Idefirix approved in EEA under conditional approval for kidney transplantation

**Actual patient has given consent to provide images

# Many milestones achieved during the last 15 months



# Imlifidase

A novel approach to eliminate pathogenic IgG

## Origins from a bacteria *Streptococcus pyogenes*

- Species of Gram-positive, spherical bacteria in the genus *Streptococcus*
- Usually known from causing a strep throat infection

## A unique IgG antibody-cleaving enzyme

- Interacts with Fc-part of IgG with extremely high specificity
- Cleaves IgG at the hinge region, generating one F(ab')2 fragment and one homo-dimeric Fc-fragment




## Inactivates IgG in 2-6 hours

- Rapid onset of action that inactivates IgG below detectable level in 2-6 hours
- IgG antibody-free window for approximately one week



# Potential indication universe




*) The EU Commission has granted conditional approval for imlifidase in highly sensitized kidney transplant patients.
**) In the US a new study has commenced targeting a BLA filing by H1 2024

# Our Business model

Leveraging our technology platform to develop new therapies targeting rare diseases with unmet medical need across a range of indications



# Idefirix® (imlifidase) has received conditional approval in the European Union

Low complexity transplants ⟵ ⟶ Higher complexity transplants

| ~70% of patients[1,2] | 15-20% of patients[1,2] | 10-15% of patients[1,2] |
|---|---|---|
| Non or less sensitized (cPRA < 20%) | Moderately sensitized (20% < cPRA < 80%) | Highly sensitized (cPRA > 80%) |
| | | Highly sensitized patients that are likely to be transplanted with a compatible donor |
| | | Highly sensitized patients unlikely to be transplanted under available KAS, including prioritization programs |

Actual patient has given consent to provide images

**Idefirix® is indicated for**

*desensitization treatment of highly sensitized adult kidney transplant patients with positive crossmatch against an available deceased donor.*

*The use of Idefirix® should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritization programs for highly sensitized patients*

**Potential patients**

idefirix® imlifidase

HANSA BIOPHARMA

[1] EDQM. (2020). International figures on donation and Transplantation 2019
[2] SRTR Database and individual assessments of allocation systems

# The kidney transplantation landscape in Europe and the U.S.

## Up to 15% of patients waiting for a new kidney are highly sensitized

### Breakdown of the kidney transplant waitlist in U.S. and EU




## ~50,000 transplants done annually in the U.S. and Europe




*Reported to be impacted by the COVID-19 pandemic

Source: Global Observatory on Donation and Transplantation, http://www.transplant-observatory.org/

Source: The U.S. Department of Health and Human Services and .irodat.org

# Our center focused and sequenced launch process will help build the foundation for Idefirix® to become a new Standard of Care in transplantation

Idefirix® is the first and only approved treatment in Europe for desensitization treatment of highly sensitized kidney transplant patients. The long-term market uptake is highly dependent on successful early experiences in key early adopter centers

*Illustrative*




**1 Build the foundation for Idefirix® in EU to become a new Standard of Care**

- Commercialize in early-launch countries focusing on leading clinics and early adopters
- Secure Pricing and Reimbursement agreements
- Ensure clinical readiness and KOL engagement
- Implement new medical guidelines through ESOT
- Increase awareness on unmet need through KOL engagement, patient organizations and medical conferences
- Initiate post approval study in Europe to support full approval and establish long-term outcomes

**"Low initial uptake and volatile growth"**

*Sales initially remain "low and volatile" between quarters during the initial launch years until early positive experiences are generated for Idefirix® to become a new SoC*

**2 Expanding internationally will lead to more accelerated growth mid term**

- Leverage experience to scale Idefirix in Europe with early-launch centers and in the five largest markets after completing market access
- Launch in the U.S. following completion of the ConfIdeS study and FDA approval
- Expand to select markets and regions beyond core markets in EU and the U.S. through partnerships
- Full marketing authorization in Europe
- Support patient and organ access for highly sensitized patients

**"More accelerated growth'**

*Expand broader and internationally*

**3 Potential label expansion will enable new growth pockets longer term**

- Commercialize in AMR in kidney upon potential approval
- Potentially expand into living donor transplantation
- Potentially expand into other solid organ transplantations such as heart and lung pre- and post transplantation (AMR)

**"Growth from pursuing new opportunities"**

*Potentially enable label expansions*

HANSA BIOPHARMA

# Recommendation by NICE is an important step forward for our commercialization efforts and for patients in England, Wales & Northern Ireland

NICE considers Idefirix® to be a clinically- and cost-effective treatment; Market access has now been secured in 7 European countries and procedures are ongoing in 11 countries, including Spain and Italy




[1]Annual kidney transplantations 2019 (pre-Corona)
*Transplantation data is from Global Observatory on Donation and Transplantation, 2019
**Pricing & reimbursement obtained in France on an early access basis

# Broad clinical pipeline in transplantation and auto-immune diseases

| Candidate/ Program | Indication | Research/ Preclinical | Phase 1 | Phase 2 | Phase 3 | Marketing Authorization | Marketed | Next Anticipated Milestone |
|---|---|---|---|---|---|---|---|---|
| Imlifidase | EU: Kidney transplantation in highly sensitized patients [1,2] | | | | | | | EU: Additional agreements around reimbursement from H2'21 |
| | US: Kidney transplantation in highly sensitized patients [1,2] | | | | | | | Completion of enrollment (64 patients) H2'22 |
| | Anti-GBM antibody disease [3] | | | | | | | Pivotal Phase 3 study expected to commence in 2022 (50 patients) |
| | Antibody mediated kidney transplant rejection (AMR) | | | | | | | First data readout H2'22 |
| | Guillain-Barré syndrome (GBS) | | | | | | | Completion of enrollment (30 patients) H2 2022 |
| | Pre-treatment ahead of gene therapy in Limb-Girdle (Partnered with Sarepta) | | | | | | | Preclinical phase |
| | Pre-treatment ahead of gene therapy in Duchenne (Partnered with Sarepta) | | | | | | | Preclinical phase |
| | Pre-treatment ahead of gene therapy in Pompe disease (Partnered with AskBio) | | | | | | | Preclinical phase |
| NiceR | Recurring treatment in autoimmune disease, transplantation and oncology | | | | | | | Completion of GLP toxicology studies in 2022 |
| EnzE | Cancer immunotherapy | | | | | | | Research phase |

[1] Results from the Phase 1 study have been published, Winstedt el al. (2015) PLOS ONE 10(7)
[2] Lorant et al American Journal of Transplantation and 03+04 studies (Jordan et al New England Journal of Medicine)
[3] Investigator-initiated study by Mårten Segelmark, Professor at the universities in Linköping and Lund

Completed
Ongoing
Planned
Post approval study running in parallel with commercial launch

HANSA BIOPHARMA

# Our unique antibody cleaving enzyme technology may have relevance across a range of indications

## Targeting rare IgG mediated diseases

**Anti-GBM paves the way for development in other autoimmune diseases**

- Rapidly progressive glomerulonephritis
- Neurological disorders
- Skin and blood disorders

**IgG-cleaving enzymes to enable or even potentiate cancer therapy**

- Allogenic stem cell (bone marrow) transplantation (HSCT)
- Enzyme-based antibody Enhancement (EnzE)




**Expanding our commercial franchises**

- Regulatory approval (conditional)
- Clinical development
- Partnership (preclinical development)
- Preclinical development
- Potential indications (currently not pursued)

**Shaping a new standard for desensitization will help enable new indications in transplantations**

- Antibody mediated rejection (AMR) in kidney transplantation
- Other transplantation types

**Exploring opportunities in gene therapy**

- Encouraging preclinical data published in Nature
- Validation through collaborations with Sarepta and AskBio
- Wide indication landscape beyond

# Hansa Biopharma is financed through 2024

$70 million non-dilutive financing transaction announced in July 2022 to support the continued development of Hansa's antibody-cleaving enzyme technology platform







*Including SEK ~750m from NovaQuest financing agreement & SEK ~100m upfront payments from Sarepta

# Upcoming milestones

Milestones subject to potential COVID-19 impact




*Guidance assumes no persistent impact or further escalation of the COVID-19 pandemic potentially forcing trial centers to reprioritize patient recruitment or even shut down again.*

HANSA BIOPHARMA


HANSA
BIOPHARMA

# Investor Relations

Visit our web site
www.hansabiopharma.com


Klaus Sindahl

Head of Investor Relations

Mobile: +46 (0) 709-298 269

Email: klaus.sindahl@hansabiopharma.com

## Calendar and events

| | |
|---|---|
| Sept 12-13, 2022 | H.C. Wainwright Global Investment Conference, New York |
| Sept 14, 2022 | MorganStanley Global Healthcare Conference, New York |
| Sept 15-16 | William Blair US Midwest/West Coast road show |
| Sept 26, 2022 | Aktiespararna Aktiedagen, Lund |
| **Oct 20, 2022** | **Interim Report for January-September 2022** |
| Oct 20, 2022 | Redeye Afterwork presentation, Gothenburg |
| Oct 21, 2022 | Redeye Lunch presentation, Stockholm |
| Oct 26, 2022 | Ökonomisk Ugebrev Life Science Conference, Copenhagen |
| Nov 23, 2022 | SEB Healthcare Seminar 2022, Stockholm |
| Nov 24, 2022 | Redeye Life Science Day, Stockholm |
| Dec 1, 2022 | Erik Penser Banks Temadag - Health Care, Stockholm |